Overview

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2. Phase II study stage: Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing Tide Pharmaceutical Co., Ltd